NOVN.CH

123.06

+1.75%↑

LONN.CH

507.8

-2.01%↓

NOVN.CH

123.06

+1.75%↑

LONN.CH

507.8

-2.01%↓

NOVN.CH

123.06

+1.75%↑

LONN.CH

507.8

-2.01%↓

NOVN.CH

123.06

+1.75%↑

LONN.CH

507.8

-2.01%↓

NOVN.CH

123.06

+1.75%↑

LONN.CH

507.8

-2.01%↓

Search

Roche Holding AG

Fermé

SecteurSoins de santé

367.2 2.11

Résumé

Variation du prix de l'action

24h

Actuel

Min

356.2

Max

367.2

Chiffres clés

By Trading Economics

Revenu

1.8B

5.5B

Ventes

15B

31B

P/E

Moyenne du Secteur

22.556

121.746

Rendement du dividende

2.7

Marge bénéficiaire

17.892

Employés

103,249

EBITDA

1.5B

8B

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

2.70%

2.26%

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-1B

288B

Ouverture précédente

365.09

Clôture précédente

367.2

Sentiment de l'Actualité

By Acuity

67%

33%

310 / 352 Classement par Healthcare

Roche Holding AG Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

29 janv. 2026, 10:07 UTC

Résultats

Roche Forecasts 2026 Growth, Cites Drug-Pipeline Strength -- Update

29 janv. 2026, 07:07 UTC

Résultats

Roche Forecasts 2026 Growth, Helped by Strength of Drug Pipeline

18 nov. 2025, 11:04 UTC

Principaux Mouvements du Marché

Roche Shares Rise After Breast-Cancer Pill Shows Positive Results in Trial

23 oct. 2025, 09:32 UTC

Résultats

Roche Raises Full-Year Earnings Outlook as U.S. Drug-Pricing Talks Continue -- Update

23 oct. 2025, 05:54 UTC

Résultats

Roche Raises Full-Year Earnings Outlook

29 janv. 2026, 11:40 UTC

Market Talk
Résultats

Roche's Guidance Seems Less Conservative Than Expected -- Market Talk

29 janv. 2026, 06:05 UTC

Résultats

Roche Expects 2026 Core EPS to Increase in High-Single Digit Range at CER

29 janv. 2026, 06:04 UTC

Résultats

Roche Expects 2026 Mid-Single-Digit Range Sales Increase at Constant Currency

29 janv. 2026, 06:03 UTC

Résultats

Roche Issues 2026 View

29 janv. 2026, 06:02 UTC

Résultats

Analysts Saw 2025 Core EPS at CHF19.70

29 janv. 2026, 06:02 UTC

Résultats

Roche: 2025 Core EPS CHF19.46

29 janv. 2026, 06:01 UTC

Résultats

Analysts Had Seen 2025 Sales At CHF61.47B

29 janv. 2026, 06:01 UTC

Résultats

Roche 2025 Sales CHF61.52B

28 janv. 2026, 11:22 UTC

Résultats

Roche's Prospects in Weight-Loss Field to be in Focus -- Earnings Preview

27 janv. 2026, 11:31 UTC

Market Talk

Roche's Weight-Loss Study Results Seem Promising -- Market Talk

27 janv. 2026, 11:24 UTC

Market Talk

Roche Might Struggle to Leave Mark in Crowded Obesity Market With CT-388 -- Market Talk

27 janv. 2026, 09:30 UTC

Market Talk

Roche's CT-388 Could Compete With Lilly's Zepbound on Obesity Efficacy -- Market Talk

27 janv. 2026, 07:52 UTC

Market Talk
Acquisitions, Fusions, Rachats

Roche Obesity Study Data Look Encouraging -- Market Talk

16 janv. 2026, 17:03 UTC

Market Talk

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

12 janv. 2026, 14:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Pharma Sector Can Spend Big on M&A -- Market Talk

22 déc. 2025, 08:48 UTC

Market Talk

U.S. Administration's Deals With Big Pharma Unveil Pricing Uncertainty -- Market Talk

19 nov. 2025, 12:47 UTC

Market Talk

Roche's Breast Cancer Drug Trial Results Surprise Positively -- Market Talk

10 nov. 2025, 12:16 UTC

Market Talk
Résultats

Roche Results for MS-Treatment Candidate Look Encouraging -- Market Talk

23 oct. 2025, 09:19 UTC

Market Talk
Résultats

Roche's Sales Slow, But Drug Pipeline Could Support Long-Term Growth -- Market Talk

23 oct. 2025, 09:11 UTC

Market Talk
Résultats

Roche Sales Miss Driven by Underperformance of Key Drugs -- Market Talk

23 oct. 2025, 05:09 UTC

Résultats

Roche 3Q Sales Up 6% At CER

23 oct. 2025, 05:07 UTC

Résultats

Roche 3Q Sales CHF14.92B

23 oct. 2025, 05:07 UTC

Résultats

Analysts Had Seen 3Q Sales At CHF15.17B

23 oct. 2025, 05:07 UTC

Résultats

Roche See Core Earnings Per Share Growth In High-Single to Low-Double-Digit Range At CER

23 oct. 2025, 05:05 UTC

Résultats

Roche Expects An Increase In Group Sales In Mid-Single-Digit Range At CER

Comparaison

Variation de prix

Roche Holding AG prévision

Note du Consensus

By TipRanks

0 ratings

0

Achat

0

Maintien

0

Vente

Sentiment

By Acuity

310 / 352Classement par Soins de santé

Sentiment de l'Actualité

Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.
help-icon Live chat